# EDGAR Filing Document

**Accession Number:** 0001728328
**File Stem:** 0001213900-25-099529
**Filing Date:** 2025-10
**Character Count:** 12409
**Document Hash:** ff98ba0d53c2610b39a6dadddcf610b7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-099529.hdr.sgml**: 20251016

**ACCESSION NUMBER**: 0001213900-25-099529

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251014

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251016

**DATE AS OF CHANGE**: 20251016

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMed Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001728328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39685
- **FILM NUMBER:** 251397626

**BUSINESS ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8
- **BUSINESS PHONE:** (604) 669-7207

**MAIL ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): October 14, 2025**

**INMED PHARMACEUTICALS INC.** 

**(Exact Name of Company as Specified in Charter)** 

---

| | | |
|:---|:---|:---|
| **British Columbia** | **001-39685** | **98-1428279** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **InMed Pharmaceuticals Inc.** <br> **Suite 1445 - 885 W. Georgia Street,** <br> **Vancouver, B.C.** <br> **Canada** | **V6C 3E8** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Company's telephone number, including area code: (604) 669-7207**

**Not applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange<br> on which registered** |
| **Common Shares, no par value** | **INM** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

<u>Appointment of Mr. John Bathery</u> 

On October 14, 2025, the board of directors (the "Board") of InMed Pharmaceuticals Inc. (the "Company") appointed Mr. John Bathery as a director and concurrently increased the size of the Board to six members, effective as of October 14, 2025. Mr. Bathery may be appointed to one or more of the committees of the Board, but the appointments have not been determined at this time. Mr. Bathery's term as a member of the Board will expire immediately before the Annual General Meeting to be held in 2025.

There are no arrangements nor understandings between Mr. Bathery, on the one hand, and the Company or any other persons, on the other hand, pursuant to which he was selected as a director of the Company. There are no related party transactions between the Company and Mr. Bathery (or any of his immediate family members) requiring disclosure under Item 404(a) of Regulation S-K. Mr. Bathery does not have any family relationship with any of the Company's other directors or executive officers.

Mr. Bathery will be entitled to receive compensation for service as a non-employee director consistent with the Company's non-employee director compensation program, which includes an annual retainer of US50,000 and may include additional amounts for serving as a Board committee member, if applicable. In connection with his appointment to the Board, Mr. Bathery executed the Company's standard form of indemnification agreement for directors.

<u>Retirement of Mr. Bryan Baldasare</u> 

On October 15, 2025, Mr. Bryan Baldasare notified the Company that he will not stand for re-election at the Company's 2025 Annual General Meeting due to increasing professional obligations. There is no disagreement between Mr. Baldasare and the Company, as defined in 17 CFR 240.3b-7, on any matter relating to the Company's operations, policies or practices.

**Item 7.01 Regulation FD Disclosure.**

On October 16, 2025, the Company issued a press release announcing the appointment of Mr. John Bathery as a director and Mr. Bryan Baldasare notified the Company that he will not stand for re-election at the Company's 2025 Annual General Meeting. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| 99.1 | [Press Release filed October 16, 2025](ea026153701ex99-1_inmed.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | INMED PHARMACEUTICALS INC. | INMED PHARMACEUTICALS INC. |
| Date: October 16, 2025 | By: | /s/ Eric A. Adams |
|  |  | Eric A. Adams |
|  |  | President and CEO |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| ![](ex99-1_001.jpg) | **NASDAQ: INM**<br>1445 – 885 West Georgia St.<br> Vancouver, BC, Canada V6C 3E8<br> Tel: +1.604.669.7207<br> Email: info@inmedpharma.com<br> www.inmedpharma.com |

---

**InMed Pharmaceuticals Appoints Mr. John Bathery to Board of Directors**

Vancouver, British Columbia – October 16, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors, effective immediately.

Mr. Bathery brings more than 30 years of experience in the pharmaceutical industry, including over 15 years in corporate development and strategic partnerships. He currently serves as Head of Global Business Development Operations & Externalization at Takeda Pharmaceuticals, where he has overseen pipeline and commercial divestitures, global alliance management, and integration of corporate transactions. Over his career, he has led and closed transactions with financial terms exceeding $60 billion across M&A, licensing, divestments, and collaborations.

Mr. Bathery's extensive background in evaluating preclinical and early-stage assets, structuring value-creating partnerships, and leading cross-functional global initiatives will be highly relevant as InMed advances both its INM-901 program for Alzheimer's disease and INM-089 program in Age-Related Macular Degeneration ("AMD") toward clinical readiness and explores potential partnerships.

**Andrew Hull, Chairman of the Board of InMed, commented:**

"We are delighted to welcome John to InMed's Board. His extensive deal-making expertise and proven ability to structure partnerships at the preclinical stage will be instrumental as we advance our development programs and pursue strategic collaborations. John's experience in global business development and corporate development will be a strong asset as we position the Company for future growth."

**Mr. John Bathery, commented:**

"I am pleased to join InMed's Board at this pivotal stage in the Company's growth. The consistent positive results seen with INM-901 across multiple parameters are particularly encouraging and highlight the strength of InMed's research. I look forward to supporting the team as we advance InMed's programs and explore strategic opportunities to maximize their potential."

**About InMed:** 

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

**Investor Contact:**

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604.416.0999

E: ir@inmedpharma.com

**Cautionary Note Regarding Forward-Looking Information:**

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, in Item 1. of the Annual Report for the period ended June 30, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.